Affordable Access

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

Authors
  • Goss, Paul E1
  • Ingle, James N
  • Martino, Silvana
  • Robert, Nicholas J
  • Muss, Hyman B
  • Piccart, Martine J
  • Castiglione, Monica
  • Tu, Dongsheng
  • Shepherd, Lois E
  • Pritchard, Kathleen I
  • Livingston, Robert B
  • Davidson, Nancy E
  • Norton, Larry
  • Perez, Edith A
  • Abrams, Jeffrey S
  • Cameron, David A
  • Palmer, Michael J
  • Pater, Joseph L
  • 1 Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA, USA. [email protected]
Type
Published Article
Journal
JNCI Journal of the National Cancer Institute
Publisher
Oxford University Press
Publication Date
Sep 07, 2005
Volume
97
Issue
17
Pages
1262–1271
Identifiers
PMID: 16145047
Source
Medline
License
Unknown

Abstract

Letrozole after tamoxifen is well-tolerated and improves both disease-free and distant disease-free survival but not overall survival, except in node-positive patients.

Report this publication

Statistics

Seen <100 times